ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

RNAZ TransCode Therapeutics Inc

1.28
-0.05 (-3.76%)
Jun 12 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 227,117
Bid Price 1.23
Ask Price 1.28
News -
Day High 1.36

Low
0.42

52 Week Range

High
128.00

Day Low 1.22
Company Name Stock Ticker Symbol Market Type
TransCode Therapeutics Inc RNAZ NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.05 -3.76% 1.28 19:52:50
Open Price Low Price High Price Close Price Prev Close
1.33 1.22 1.36 1.23 1.33
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
940 227,117 $ 1.27 $ 288,319 - 0.42 - 128.00
Last Trade Time Type Quantity Stock Price Currency
19:55:27 4 $ 1.23 USD

TransCode Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
771.75k 627.44k - 0 -18.55M -29.56 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

TransCode Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No RNAZ Message Board. Create One! See More Posts on RNAZ Message Board See More Message Board Posts

Historical RNAZ Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week1.341.430.961.22656,043-0.06-4.48%
1 Month0.731.990.70021.301,204,3250.5575.34%
3 Months0.66932.010.421.051,345,5140.610791.24%
6 Months8.408.400.422.531,347,631-7.12-84.76%
1 Year108.40128.000.4227.462,505,078-107.12-98.82%
3 Years4,800.005,600.000.42956.761,726,299-4,798.72-99.97%
5 Years4,800.005,600.000.42956.761,726,299-4,798.72-99.97%

TransCode Therapeutics Description

TransCode Therapeutics Inc is an RNA oncology company. It is created to defeat the cancer through the intelligent design and effective delivery of RNA therapeutics. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which has the potential to produce regression without recurrence in a range of cancers, including breast, pancreatic, ovarian and colon cancer, glioblastomas and others.

Your Recent History

Delayed Upgrade Clock